{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:54:21Z","timestamp":1761173661417,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.purol.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T16:21:16Z","timestamp":1563034876000},"page":"510-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Valeur pronostique de la testost\u00e9ron\u00e9mie lors de l\u2019hormonoth\u00e9rapie intermittente du cancer de la prostate"],"prefix":"10.1016","volume":"29","author":[{"given":"A.","family":"Vallat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Leb\u00e2cle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 12","key":"10.1016\/j.purol.2019.06.002_bib0120","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de Canc\u00e9rologie de l\u2019AFU\u2013Actualisation 20182020\u00a0: cancer de la prostate","volume":"28","author":"Rozet","year":"2018","journal-title":"Prog En Urol"},{"issue":"4","key":"10.1016\/j.purol.2019.06.002_bib0125","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.eururo.2014.06.044","article-title":"Intermittent androgen deprivation therapy with antagonist: really new information?","volume":"66","author":"Mottet","year":"2014","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.purol.2019.06.002_bib0130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.purol.2019.06.002_bib0135","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.purol.2019.06.002_bib0140","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.eururo.2015.10.007","article-title":"Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND)","volume":"69","author":"Schulman","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2019.06.002_bib0145","doi-asserted-by":"crossref","first-page":"11002","DOI":"10.1063\/1.3697848","article-title":"A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy","volume":"2","author":"Portz","year":"2012","journal-title":"AIP Adv"},{"issue":"14","key":"10.1016\/j.purol.2019.06.002_bib0150","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1158\/0008-5472.CAN-13-3162","article-title":"Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method","volume":"74","author":"Morken","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.purol.2019.06.002_bib0155","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0022-5347(05)66910-8","article-title":"A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy","volume":"164","author":"Nejat","year":"2000","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2019.06.002_bib0160","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.juro.2008.06.029","article-title":"Testosterone recovery after prolonged androgen suppression in patients with prostate cancer","volume":"180","author":"Yoon","year":"2008","journal-title":"J Urol."},{"issue":"4\u00a0Pt 1","key":"10.1016\/j.purol.2019.06.002_bib0165","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","article-title":"Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy","volume":"178","author":"Morote","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2019.06.002_bib0170","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S1166-7087(16)30705-9","article-title":"Recommandations en onco-urologie 2016-2018\u00a0du CCAFU\u00a0: cancer de la prostate","volume":"27","author":"Rozet","year":"2016","journal-title":"Prog En Urol"},{"issue":"3","key":"10.1016\/j.purol.2019.06.002_bib0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/pcan.2012.12","article-title":"Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy","volume":"15","author":"Tunn","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.purol.2019.06.002_bib0180","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1743-6109.2010.02169.x","article-title":"Intermittent androgen suppression in prostate cancer: testosterone levels and its implication","volume":"8","author":"Mearini","year":"2011","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.purol.2019.06.002_bib0185","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2008.02.024","article-title":"Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study","volume":"54","author":"Irani","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2019.06.002_bib0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clgc.2014.08.003","article-title":"Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer","volume":"13","author":"Kuo","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.purol.2019.06.002_bib0195","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.juro.2012.01.080","article-title":"The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression","volume":"187","author":"Ng","year":"2012","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2019.06.002_bib0200","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4321\/S1137-66272015000200003","article-title":"[Quality of life in patients diagnosed of prostate cancer treated with continuous androgen deprivation therapy vs. intermittent therapy]","volume":"38","author":"Sierra Labarta","year":"2015","journal-title":"An Sist Sanit Navar"},{"issue":"4","key":"10.1016\/j.purol.2019.06.002_bib0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","article-title":"Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer","volume":"2","author":"Hershman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.purol.2019.06.002_bib0210","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.purol.2019.06.002_bib0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eururo.2012.04.035","article-title":"Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?","volume":"64","author":"Keating","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2019.06.002_bib0220","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2019.06.002_bib0225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.purol.2019.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.juro.2016.12.022","article-title":"Risks of serious toxicities from intermittent versus continuous androgen deprivation therapy for advanced prostate cancer: a population-based study","volume":"197","author":"Tsai","year":"2017","journal-title":"J Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719301538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719301538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:31:31Z","timestamp":1761114691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708719301538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1166708719301538"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2019.06.002","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valeur pronostique de la testost\u00e9ron\u00e9mie lors de l\u2019hormonoth\u00e9rapie intermittente du cancer de la prostate","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}